Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Next Previous
Drug Profile

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482

Latest Information Update: 20 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Herlev Hospital; Multiple Myeloma Research Consortium; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCLAs Jonsson Comprehensive Cancer Center; University Hospital of Essen; University of Miami; University of Pittsburgh
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Chordoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Uveal melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Fallopian tube cancer; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Glioblastoma

Most Recent Events

  • 19 Feb 2025 Bristol-Myers Squibb completes phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Switzerland, Australia, France, Italy, Spain and USA (PO) (NCT03459222) (EudraCT2018-000058)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top